Medical Professionals Reference (MPR)Brenzavvy Now Available for Adults with Type 2 Diabetes

TheracosBio has partnered with the Mark Cuban Cost Plus Drug Company to distribute Brenzavvy.

Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 inhibitor, recently received approval for use as an adjunct to diet and exercise to enhance glycemic control in adult type 2 diabetes patients. This significant stride in the diabetes therapy market emanates from the TheracosBio program and is anticipated to lower treatment cost barriers, thereby expanding utilization.

Key Points:

• Brenzavvy, backed by data from 23 clinical trials involving more than 5,000 adults with type 2 diabetes, is now approved.
• The drug is administered as a 20mg tablet, once daily in the morning.
• Renal function and volume status should be assessed before initiating Brenzavvy treatment; it’s not recommended for patients with an eGFR less than 30mL/min/1.732 and contraindicated in dialysis patients.

Additional Points:

• A 30-day supply of Brenzavvy is priced at $47.85 plus shipping and handling.

Conclusion:

• The launch of Brenzavvy heralds the first phase of TheracosBio’s mission to bring cost-effective novel medications to the US population.

Endocrinology Latest Posts

• Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesApril 19, 2024
• Are Plant-based Meat Substitutes Really Better for the Heart than Meat Options?April 17, 2024
• Corticosteroids: Giving and Taking AwayApril 15, 2024
• Acquired Reactive Perforating Collagenosis in a Patient with DiabetesApril 15, 2024